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from outcome analysis. Of the remaining 28 patients, ﬁve
HSCT recipients (4 allo and 1 auto) have died (18%). All pa-
tients who died were in the lower respiratory tract infection
group and their death was directly attributed to pulmonary
complications as a result of respiratory virus infections. Two
patients died from adenovirus pneumonitis and ARDS. Two
patients died from severe parainﬂuenza infection with
deterioration of symptoms and respiratory failure despite
treatment with ribavarin and the last patient had ARDS from
RSV infection. No chronic pulmonary complication or allo-
immune lung syndrome was observed among the remaining
23 survivors with a median follow-up time of 3.8 years (8
months-10.3 years).
This study supports the signiﬁcant TRM from respiratory
virus infection diagnosed within the ﬁrst 100 days post HSCT
particularly in patients presented with lower respiratory
tract infection. Higher mortality was observed among allo
recipients. Every effort should be made to prevent respira-
tory virus infections early post HSCT.295
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Introduction: Falls are a common cause of morbidity and
mortality among hospitalized patients in the United States.
Patients with cancer are vulnerable to falls with injury as a
result of complex medical regimens, impaired performance
status, and chemotherapy toxicities such as neuropathy.
Predictors of falls in the general oncology population
include abnormal gait, presence of metastasis, antide-
pressant and antipsychotic medication use, and blood
product use. Risk factors for falls in the hematopoietic
stem cell transplant (HSCT) population are not as well
understood.
Methods: We performed a retrospective review of patients
admitted to Dana-Farber/Brigham and Women’s Cancer
Center from 01/2011 to 12/2012, who had a fall during their
admission to a HSCT service. Patients were classiﬁed as either
fall or fall with injury (FWI). Our primary objective was to
describe characteristics of hospitalized HSCT patients who
experience a FWI, including medications administered in the
24 hours prior to the fall.
Results: There were 91 falls identiﬁed in 81 patients. One
patient was excluded from the analysis due to incomplete
electronic medical records. Nine patients had more than
one fall. Thirty-two falls resulted in FWI. Fifty-seven falls
(62.6%) occurred during an index admission for HSCT. This
represents 5.48% of our index admissions. Patients had a
history of HSCT or were undergoing myeloablative HSCT
(n¼25), reduced intensity conditioning HSCT (n¼19) or
autologous HSCT (n¼36). Patient and transplant character-
istics were compared between patients who had falls
without injury and patients who had FWI. There was no
signiﬁcant difference in age (p¼0.99), gender (p¼0.65),
cancer diagnosis (p¼0.84), hospital admission team
(p¼0.99), admission type (p¼0.14) or transplant type
(p¼0.80) between patients with falls and FWI. Inmultivariate analysis, benzodiazepine use (p¼0.016) and
Morse Fall score  45 (p¼0.031) were associated with
increased risk of FWI, whereas diuretic use (p¼0.029),
presence of heart disease (p¼0.023) and prior fall (p¼0.015)
were associated with decreased risk of FWI.
Conclusions: Falls are common in patients hospitalized for
HSCT. Benzodiazepine use and high Morse Fall score predict
for an increased risk of injury after a fall event. Adequate
assessment and management of these modiﬁable fall risk
factors, including decreasing our benzodiazepine use and
early identiﬁcation of at risk patients may help prevent FWI
in our HSCT population.296
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Respiratory syncytial virus (RSV) in the immunocompromised
adult can lead to signiﬁcant morbidity and mortality. Most
immunocompromised patients with RSV pneumonia present
to a health care facility with an upper respiratory tract infec-
tionw1 week prior to the onset of pneumonia. Overall, 40%e
50% of RSV upper respiratory tract infections (URTI) in HCT
recipients will progress to pneumonia. RSV pneumonia in HCT
recipients is associated with fatality rates as high as 70e80%.
Treatment of RSV pneumonia is primarily supportive. The role
of speciﬁc antiviral therapy remains uncertain. We retro-
spectively reviewed RSV-infected patients with upper or
lower respiratory tract infection (LRTI) diagnosed by antigen
testing, polymerase chain reaction and/or culture from
January 2007 through March 2013. In general, clinically stable
URTI patients with an absolute lymphocyte count (ALC)> 300
received only supportive care. Patients presenting with URTI
and lymphopenia (ALC  300) were preferentially treated
with a course of inhaled ribavirin (IR) alone. Those presenting
with LRTI were preferentially treated with IR in combination
with the RSV-speciﬁc humanized monoclonal antibody, Pal-
ivizumab. We identiﬁed 60 consecutive patients who were
diagnosed with RSV (median age 52 [21 - 72]) - 35 had URTI
and 25 had LRTI. Forty-one (71%) of the patients had received
an allogeneic transplant, seven (12%) were post autologous
transplant, while 10 (17%) were receiving treatment for acute
leukemia. Of the allogeneic transplant patients, 31 (51.6 %)
were receiving immunosuppressants and 24 (40%) were being
